Adaptimmune Therapeutics Plc, which is developing T cell therapies, has hired Mark Dudley to oversee the manufacturing and future commercialisation of its products. Dr Dudley was previously director of new cell products at Novartis where he was responsible for establishing scalable GMP-compliant production strategies. Prior to this, he was director of the cell production facility at the US National Cancer Institute.
Dr Dudley earned a PhD in biological sciences at Stanford University and did postdoctoral work at the University of Pennsylvania and at the Jackson Laboratory, both in the US.
Adaptimmune announced the appointment on 9 January 2017.
Copyright 2017 Evernow Publishing Ltd